​Sickle Cell Disease Regional Care Excellence (SoRCE) Program
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Sickle Cell Disease Regional Care Excellence Program (SoRCE) aims to enhance the health outcomes of individuals with sickle cell disease (SCD) by broadening access to quality care and monitoring quality of life indicators. With around 100,000 people affected in the United States, early treatment is crucial to prevent or reduce severe complications such as painful episodes, silent strokes, and early mortality. Despite newborn screening, less than half of children with SCD receive the necessary treatment, and challenges persist as these patients transition into adolescence and adulthood, partly due to ongoing provider education on emerging therapies. The program is structured into seven regions, each led by a Regional Coordinating Hub (RCH) that partners with clinical and community organizations within its area. These hubs drive continuous quality improvement initiatives focused on increasing access to care and elevating treatment standards for SCD patients. Administered by the Health Resources and Services Administration under the Department of Health and Human Services, the program emphasizes collaborative regional efforts to address gaps in care and improve long-term health outcomes for individuals living with sickle cell disease.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Sickle Cell Disease Regional Care Excellence Program (SoRCE) is to improve the health of people with sickle cell disease (SCD) by expanding access to care, improving the quality of care, and tracking quality of life indicators. There are approximately 100,000 people in the United States with SCD. Treatment starting in early childhood can prevent or reduce complications such as severe pain episodes, silent strokes, and premature death. Despite universal identification at birth, fewer than half of children with SCD receive needed treatment. As these children become adolescents and transition to adulthood many are not appropriately identified as candidates for disease-modifying therapies, in part because their doctors are still learning how to use the latest treatments. The program is made up of seven regions with one award recipient per region serving as a Regional Coordinating Hub (RCH). Each award recipient will work with clinical and community-based partners in their region and engage in continuous quality improvement (CQI) initiatives to improve access and quality of care.
